Jim joined Dermavant Sciences in 2016 from GSK where he served as head of the dermatology clinical development group since 2011. Jim began his career in pharmaceutical medicine over 17 years ago and has held positions of increasing responsibility in clinical development and medical affairs at GSK, Graceway Pharmaceuticals, Johnson and Johnson, and 3M Pharmaceuticals. His leadership and contributions in the development of a number of dermatological treatments, including Aldara and Stelara, have helped Jim become one of the leaders in dermatology development. Jim earned a B.A. in biochemistry from Carleton College, in Northfield, Minnesota and graduated from the Medical Scholars Program at the University of Illinois, receiving a Ph.D. in biochemistry and an M.D. from the College of Medicine.
Rebecca joined Dermavant Sciences in August 2016. Rebecca was previously employed at PAREXEL International, where she served as the Head of the GSK Business Unit. Rebecca also worked for GSK for twenty-four years, holding a variety of leadership positions across multiple therapy areas and across Phases II – IV in data management, clinical research and clinical operations, the last being Global Operations Head for Stiefel, a GSK company focused on dermatology. While with GSK, she supported multiple NDAs leading to approvals for Serevent®, Flovent®, Advair® and Breo®. Rebecca received her B.S. from Virginia Tech, and her M.A. from Duke University.
Jane Bethea serves as the Project Management and Portfolio Director at Dermavant Sciences. Jane joined Dermavant in August 2016 from Roivant Sciences, where she served as Project Management Director since March 2014. Prior to Roivant, she spent 14 years as a project manager at GlaxoSmithKline supporting both pre-clinical and clinical stage development programs. During that time, she also provided planning support for more than 14 regulatory submissions and worked on numerous development programs with external alliance partners. Jane received her BSBA from North Carolina Wesleyan College.
Adam joined Dermavant Sciences in June 2016 and leads medical affairs and business development efforts. Adam previously worked as a generalist in business development at Roivant Sciences, Inc., evaluating opportunities across the dermatology, women’s and men’s health, and rare disease spaces. Adam received his PhD in Molecular Biophysics and Biochemistry from Yale University, and his BA in Chemistry with highest honors and highest distinction from UNC-Chapel Hill.